MedTrace Logo

Recovery of Muscle Function After Deep Neuromuscular Block by Means of Diaphragm Ultrasonography

NCT02698969 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2016-10-25

No results posted yet for this study

Summary

Diaphragm ultrasonography as a diagnostic tool in order to demonstrate the superiority of Sugammadex vs. AChEI in facilitating post-operative neuromuscular recovery.

Conditions

  • Post-operative Residual Curarization

Interventions

DRUG

Sugammadex

DEVICE

Diaphragm Ultrasonography

Prior to induction of anesthesia each enrolled patients, ultrasonography diaphragm evaluation will be performed using an ESAOTE ultrasound machine (ESAOTE MyLab, Genova, Italy) by assessing the TF and amplitude of excursion.

DRUG

Neostigmine

DRUG

Atropine

DEVICE

Neurumuscual monitoring

Neuromuscular monitoring assesses muscle recovery after deep neuromuscular block through trainf of four and post tetanic count method

DRUG

Rocuronium

Rocuronium will be administered 0.6 mg\*kg-1 to reach neuromuscular block at the induction of general anesthesia and 0.15 mg\*kg-1 when PTC elicits more than 5 twitches in order to maintain a deep neuromuscular block

DRUG

Fentanyl

Fentanest will be administered 2 mcg\*kg-1 at the induction of general anesthesia and titrated 0.5 mcg\*kg-1 every 30 minutes

DRUG

Propofol

Propofol will be administered 2 mg\*kg-1 at the induction of general anesthesia

DRUG

Sevoflurane

Sevoflurane will be administered at 1.0 MAC in an air/oxygen mixture

Sponsors & Collaborators

Principal Investigators

  • Chiara Adembri, MD · University of Florence

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2017-02-28
Completion
2017-07-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02698969 on ClinicalTrials.gov